Polymeric Nanozyme with SOD Activity Capable of Inhibiting Self- and Metal-Induced α-Synuclein Aggregation

Area of Science:

• Biomaterials Science
• Neuroscience
• Nanotechnology

Background:

• Parkinson's disease (PD) is a complex neurodegenerative disorder with no known cure.
• Key pathological hallmarks of PD include alpha-synuclein aggregation and oxidative stress.
• Current treatments for PD manage symptoms but do not halt disease progression.

Purpose of the Study:

• To develop a multifunctional nanozyme capable of addressing both alpha-synuclein aggregation and oxidative stress in Parkinson's disease.
• To investigate the therapeutic potential of a novel nanozyme designed to inhibit alpha-synuclein fibrillation and reduce oxidative damage.

Main Methods:

• Synthesis of a multifunctional nanozyme by grafting a pyridinophane ligand onto biodegradable PEGylated polyester nanoparticles.
• Coordination of CuII ions to the nanozyme to impart superoxide dismutase (SOD) activity.
• Evaluation of the nanozyme's ability to inhibit alpha-synuclein aggregation and its SOD activity in vitro.

Main Results:

• The synthesized nanozyme demonstrated significant superoxide dismutase activity.
• The nanozyme effectively inhibited the self-induced aggregation of alpha-synuclein into amyloid fibrils.
• A cooperative effect between the chelator and polymer component resulted in a notable reduction in CuII-induced alpha-synuclein aggregation.

Conclusions:

• The developed multifunctional nanozyme presents a promising dual-action therapeutic strategy for Parkinson's disease.
• This nanozyme effectively targets key pathological mechanisms of PD, including alpha-synuclein aggregation and oxidative stress.
• Further research into this nanozyme could lead to novel treatments for Parkinson's disease.